N/A
Loading page data
Please wait a moment
Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500
Orosomucoid glycoprotein is slow acute-phase protein, Orosomucoid glycoprotein testing done in the diagnosis and monitoring of inflammatory bowel disease (IBD) & liver functioning. In human there are ORM1 and ORM2 isoforms of orosomucoid glycoprotein, orosomucoid glycoprotein testing helps to determine the orosomucoid glycoprotein’s isoform from the blood.
Orosomucoid glycoprotein testing based on the principle of Immuno turbidimetry method. Orosomucoid glycoprotein testing is majorly applicable in the early detection of the Crohn’s disease. For the orosomucoid glycoprotein testing serum and plasma, both can be taken for the analysis of orosomucoid glycoprotein level in body fluids.
Reduced serum orosomucoid level is mainly associated with the liver function and vitamin A deficiency. Here, the impaired functioning of the liver can be determined by the orosomucoid glycoprotein testing.
In the liver impairment, haptoglobin level gets rises, the increased level of orosomucoid in the blood leads to the induction of the inflammatory processes in body.
Rising patient pool suffering from liver disorders may drive the orosomucoid glycoprotein testing market. People suffering from Crohn’s disease like may show the fueling growth for orosomucoid glycoprotein testing market. Disease conditions like vitamin A deficiency and malnutrition will show the additional demand of the orosomucoid glycoprotein testing market.
A number of people suffering from inflammatory disorders like inflammatory bowel syndrome, GIT complications expected to show the high revenue for the orosomucoid glycoprotein testing market. Alternative diagnosis methods like CT scan, endoscopy may show the slower growth for orosomucoid glycoprotein testing market.
Awareness of the people about the liver and kidney-related disorders may show the stagnancy in the orosomucoid glycoprotein testing market.
